SAGE THERAPEUTICS INC (SAGE)

Company Profile

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 487 full-time employees. The company went IPO on 2014-07-18. The firm has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The firm is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. The company is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Company Info

SAGE THERAPEUTICS INC

215 1st St

Cambridge MASSACHUSETTS 02142

P: 16172998380

CEO: Barry E. Greene

Employees: 487

Website: https://www.sagerx.com/